Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group

Data from a multicenter, retrospective analysis of real-world use of ruxolitinib in the treatment of patients with polycythemia vera showed that, after 3 months follow-up, ruxolitinib significantly reduced hematocrit levels (P < .001), phlebotomy requirement (P < .001), leucocytes (P = .044), and disease-related symptoms (P < .001). In terms of safety, only 6% of patients permanently discontinued ruxolitinib treatment.